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   Dear Sir, 
We read with interest the narratives by Schwartz and DeFronzo (1) and Umpierrez and 
Korytkowski (2) relating to the use of incretin-based therapy in the care of hospitalized 
patients with hyperglycemia. We have performed a number of mechanistic studies to evaluate 
incretin-based therapies in the critically ill that were not referred to (3-5). In these exogenous 
glucagon-like peptide-1 (GLP-1) was shown to attenuate the glycaemic response to enteral 
nutrient in mechanically-ventilated critically ill patients both with, and without, pre-existing 
type 2 diabetes, and associated with stimulation of serum insulin and suppression of plasma 
glucagon (3; 5). Enteral nutrition can be administered directly into the stomach or small 
intestine, and the route of feeding is a major determinant of glucose-lowering that occurs with 
GLP-1. We observed that GLP-1 slows gastric emptying when the emptying rate is relatively 
‘normal’, but not when emptying is already abnormally slow, which is often the case in the 
critically ill (4).   
 
It is recognized that the use of insulin has substantial limitations, particularly as excess 
dosing precipitates hypoglycemia and, despite sophisticated algorithms, glycemic variability 
remains a major problem (1; 6). GLP-1 also has potential advantages over insulin, including 
putative beneficial cardiac effects, and its use has the capacity to reduce nursing workloads 
(1; 2). Neither narrative, however, discussed the concept that hyperglycemia is not the same 
insult in every patient, rather, that patients with critical illness-induced hyperglycemia should 
potentially be treated differently to those patients with pre-existing hyperglycemia, associated 
with diabetes, that is exacerbated by critical illness (6). Rapid glucose-lowering with, or 
without, overt hypoglycemia may indeed be harmful in the latter group, and the capacity of 
GLP-1 to lower glycemia more gradually may lead to improved outcomes (6). Another potential advantage is that there is no impediment to intravenous administration of an agent in 
the critically ill. Nauck and colleagues have recently summarized the evidence that 
intravenous administration of GLP-1 or its agonists may be more effective, with less adverse 
events, than subcutaneous administration (7). While the ‘normalization’ of glycemia did not 
occur in all critically ill patients we studied, we have not observed hypoglycemia or vomiting 
following intravenous administration of GLP-1 in this group (3-5). 
 
While we agree with Schwartz and DeFronzo (1) that the use of incretin-based therapies in 
hospitalized patients is appealing, our experience would support the view of Umpierrez and 
Korytkowski (2) that insulin is a proven therapy, albeit one with major limitations, and 
should currently remain the treatment of choice. We suggest that additional data relating to: 
(i) optimizing incretin-based regimens - such as whether the intact peptide, agonists, dipeptyl-
peptidase 4 (DPP-4) inhibitors and/or glucose-dependent insulinotropic polypeptide should 
be used; (ii) whether GLP-1/agonists are effective as monotherapy (which we would favour) 
and, if so, which patients will respond, or which are more appropriately treated using GLP-
1/agonists in combination with insulin; and (iii) cardiovascular safety, should be sought 
promptly, as this information is important prior to wide-spread use of incretin-based regimens 
in hospitalized patients. 
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